Kilinc Y B, Sari L, Toprak H, et al. Ovarian granulosa cell tumor: a clinicoradiologic series with literature review[J]. Curr Med Imaging,2021,17(6):790-797.
[5]
Abuali S M, Asarian A, Xiao P. Synchronous granulosa cell tumor of the ovary and endometrial adenocarcinoma[J]. J Surg Case Rep, 2022(4):rjac109.
[2]
Li X, Tian B, Liu M, et al. Adult-type granulosa cell tumor of the ovary[J]. Am J Cancer Res, 2022,12(8):3495-3511.
[6]
Causa A P, Nicola R, Lipsich F, et al. Characterization of ovarian granulosa cell tumors using magnetic resonance imaging[J]. Med Res Arch, 2022, 10(6).
[3]
Kitajima M, Kajimura I, Kitajima Y, et al. AMH producing purely cystic virilizing adult granulosa cell tumor in 17 years old girl: a case report and review of literatures[J]. J Ovarian Res,2023, 16(1):52.
[7]
Matsuki M, Numoto I, Suzuki A, et al. Magnetic resonance imaging of recurrent adult granulosa cell tumor of the ovary: a retrospective analysis of 11 cases[J]. J Comput Assist Tomogr, 2020,44(6):887-892.
[4]
Lee W, Kim Y M, Kim H J. Adult-type granulosa cell tumor of the testis: a case report with immunohistochemical study[J]. Urol Case Rep, 2021, 38:101612.
[8]
Javadi S, Ganeshan D M, Jensen C T, et al. Comprehensive review of imaging features of sex cord-stromal tumors of the ovary[J]. Abdom Radiol (NY), 2021, 46(4):1519-1529.
[5]
Abuali S M, Asarian A, Xiao P. Synchronous granulosa cell tumor of the ovary and endometrial adenocarcinoma[J]. J Surg Case Rep, 2022(4):rjac109.
[9]
Meurs H S, Bleeker M C, Velden J, et al. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study[J]. Int J Gynecol Cancer, 2013, 23(8):1417-1422.
[6]
Causa A P, Nicola R, Lipsich F, et al. Characterization of ovarian granulosa cell tumors using magnetic resonance imaging[J]. Med Res Arch, 2022, 10(6).
Matsuki M, Numoto I, Suzuki A, et al. Magnetic resonance imaging of recurrent adult granulosa cell tumor of the ovary: a retrospective analysis of 11 cases[J]. J Comput Assist Tomogr, 2020,44(6):887-892.
[11]
Roze J F, van Meurs H S, Monroe G R, et al.[18F] FDG and[18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary[J]. Oncotarget, 2021, 12(7):665-673.
[8]
Javadi S, Ganeshan D M, Jensen C T, et al. Comprehensive review of imaging features of sex cord-stromal tumors of the ovary[J]. Abdom Radiol (NY), 2021, 46(4):1519-1529.
Meurs H S, Bleeker M C, Velden J, et al. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study[J]. Int J Gynecol Cancer, 2013, 23(8):1417-1422.
[13]
Parikshaa G, Ariba Z, Pranab D, et al. Juvenile granulosa cell tumor of the ovary: a comprehensive clinicopathologic analysis of 15 cases[J]. Ann Diagn Pathol, 2021, 52:151721.
Roze J F, van Meurs H S, Monroe G R, et al.[18F] FDG and[18F]FES positron emission tomography for disease monitoring and assessment of anti-hormonal treatment eligibility in granulosa cell tumors of the ovary[J]. Oncotarget, 2021, 12(7):665-673.
[15]
Ordulu Z. Update on ovarian sex cord-stromal tumors[J]. Surg Pathol Clin, 2022, 15(2):235-258.
Pilsworth J A, Cochrane D R, Neilson S J, et al. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease[J]. J Pathol Clin Res, 2021, 7(3):243-252.
[17]
Mubeen A, Martin I, Dhall D. High-grade transformation in adult granulosa cell tumor: potential diagnostic challenges and the utility of molecular testing[J]. Int J Surg Pathol, 2022,30(6):668-672.
[13]
Parikshaa G, Ariba Z, Pranab D, et al. Juvenile granulosa cell tumor of the ovary: a comprehensive clinicopathologic analysis of 15 cases[J]. Ann Diagn Pathol, 2021, 52:151721.
[18]
Dogan I, Aydin E, Topuz S, et al. Hormonal therapy in pretreated patients with recurrent ovary granulosa cell tumor[J]. J Pharm Pract, 2022, 89:71900221129679.
Qian X, Cong Z, Lai J. Ovarian granulosa cell tumor initially presenting as a giant liver mass radiologically mimicking primary cystic cholangiocarcinoma[J]. In Vivo, 2023, 37(2):734-737.
[15]
Ordulu Z. Update on ovarian sex cord-stromal tumors[J]. Surg Pathol Clin, 2022, 15(2):235-258.
[20]
McMullen E R, Huang T, Skala S L. Large ovarian follicle cyst: benign mimic of cystic adult granulosa cell tumor[J]. Int J Gynecol Pathol, 2022, 41(3):289-291.
[16]
Pilsworth J A, Cochrane D R, Neilson S J, et al. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease[J]. J Pathol Clin Res, 2021, 7(3):243-252.
[17]
Mubeen A, Martin I, Dhall D. High-grade transformation in adult granulosa cell tumor: potential diagnostic challenges and the utility of molecular testing[J]. Int J Surg Pathol, 2022,30(6):668-672.
[21]
Ukah C O, Ikpeze O C, Eleje G U, et al. Adult granulosa cell tumor associated with endometrial carcinoma: a case report[J]. J Med Case Rep, 2011, 5:340.
[18]
Dogan I, Aydin E, Topuz S, et al. Hormonal therapy in pretreated patients with recurrent ovary granulosa cell tumor[J]. J Pharm Pract, 2022, 89:71900221129679.
[22]
Boyraz B, Watkins J C, Soubeyran I, et al. Cystic granulosa cell tumors of the ovary: an analysis of 80 cases of an often diagnostically challenging entity[J]. Arch Pathol Lab Med, 2022, 146(12):1450-1459.
[19]
Qian X, Cong Z, Lai J. Ovarian granulosa cell tumor initially presenting as a giant liver mass radiologically mimicking primary cystic cholangiocarcinoma[J]. In Vivo, 2023, 37(2):734-737.
[23]
Nikas I P, Sepsa A, Kleidaradaki E, et al. EUS-FNA diagnosis of a metastatic adult granulosa cell tumor in the stomach[J]. Lab Med, 2022, 53(5):533-536.
[20]
McMullen E R, Huang T, Skala S L. Large ovarian follicle cyst: benign mimic of cystic adult granulosa cell tumor[J]. Int J Gynecol Pathol, 2022, 41(3):289-291.
[24]
Guidi S, Berghella V, Scambia G, et al. Adult granulosa cell tumor in pregnancy: a new case and a review of the literature[J]. Healthcare (Basel), 2021, 9(11):1455.
[21]
Ukah C O, Ikpeze O C, Eleje G U, et al. Adult granulosa cell tumor associated with endometrial carcinoma: a case report[J]. J Med Case Rep, 2011, 5:340.
[25]
Zhao D, Zhang Y, Ou Z, et al. Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary[J]. J Ovarian Res,2020,13(1):19.
[22]
Boyraz B, Watkins J C, Soubeyran I, et al. Cystic granulosa cell tumors of the ovary: an analysis of 80 cases of an often diagnostically challenging entity[J]. Arch Pathol Lab Med, 2022, 146(12):1450-1459.
[26]
Cui M H, Zhang X W, Zhao L P, et al. Disseminated ovarian granulosa cell tumor after laparoscopic surgery: two case reports[J]. Medicine (Baltimore), 2021, 100(15):e25176.
[23]
Nikas I P, Sepsa A, Kleidaradaki E, et al. EUS-FNA diagnosis of a metastatic adult granulosa cell tumor in the stomach[J]. Lab Med, 2022, 53(5):533-536.
[27]
Ebina Y, Yamagami W, Kobayashi Y, et al. Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: a JSGO-JSOG joint study[J]. Gynecol Oncol, 2021, 163(2):269-273.
[24]
Guidi S, Berghella V, Scambia G, et al. Adult granulosa cell tumor in pregnancy: a new case and a review of the literature[J]. Healthcare (Basel), 2021, 9(11):1455.
[28]
Zhao D, Zhang Y, Ou Z, et al. Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary[J]. J Ovarian Res, 2020,13(1):19.
[25]
Zhao D, Zhang Y, Ou Z, et al. Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary[J]. J Ovarian Res,2020,13(1):19.
[29]
Coquard I, Harter P, Lorusso D, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR/ENGOT-ov7 randomized clinical trial[J]. JAMA Oncol, 2020, 6(12):1923-1930.
[26]
Cui M H, Zhang X W, Zhao L P, et al. Disseminated ovarian granulosa cell tumor after laparoscopic surgery: two case reports[J]. Medicine (Baltimore), 2021, 100(15):e25176.
[30]
Moon A S, Dorigo O. Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary[J]. Gynecol Oncol Rep, 2021, 36:100770.
[27]
Ebina Y, Yamagami W, Kobayashi Y, et al. Clinicopathological characteristics and prognostic factors of ovarian granulosa cell tumors: a JSGO-JSOG joint study[J]. Gynecol Oncol, 2021, 163(2):269-273.
[31]
Yasukawa M, Matsuo K, Matsuzaki S, et al. Management of recurrent granulosa cell tumor of the ovary: contemporary literature review and a proposal of hyperthermic intraperitoneal chemotherapy as novel therapeutic option[J]. J Obstet Gynaecol Res, 2021 , 47(1):44-51.
[28]
Zhao D, Zhang Y, Ou Z, et al. Characteristics and treatment results of recurrence in adult-type granulosa cell tumor of ovary[J]. J Ovarian Res, 2020,13(1):19.
[32]
Summey R M, Rader J S, Moh M, et al. A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor[J]. Gynecol Oncol Rep, 2022, 44:101118.
[29]
Coquard I, Harter P, Lorusso D, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR/ENGOT-ov7 randomized clinical trial[J]. JAMA Oncol, 2020, 6(12):1923-1930.
[33]
Foster K I, Flores L A, Kamat R, et al. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors[J]. Am J Obstet Gynecol, 2023, 228(6):724.
[30]
Moon A S, Dorigo O. Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary[J]. Gynecol Oncol Rep, 2021, 36:100770.
[34]
Huang C Y, Cheng M, Lee N R, et al. Comparing paclitaxel-carboplatin with paclitaxel-cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer[J]. Int J Environ Res Public Health, 2020, 17(7):2213.
[31]
Yasukawa M, Matsuo K, Matsuzaki S, et al. Management of recurrent granulosa cell tumor of the ovary: contemporary literature review and a proposal of hyperthermic intraperitoneal chemotherapy as novel therapeutic option[J]. J Obstet Gynaecol Res, 2021 , 47(1):44-51.
[35]
Färkkilä A, Pihlajoki M, Tauriala H, et al. Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro[J]. J Clin Endoc Metab, 2011, 96(12):E1973-81.
[32]
Summey R M, Rader J S, Moh M, et al. A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor[J]. Gynecol Oncol Rep, 2022, 44:101118.
[36]
Tao X, Sood A K, Deavers M T, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors[J]. Gynecol Oncol, 2009, 114(3):431-436.
[37]
How J A, Jazaeri A, Westin S N, et al. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial[J]. Invest New Drugs, 2021, 39(3):829-835.
[33]
Foster K I, Flores L A, Kamat R, et al. Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors[J]. Am J Obstet Gynecol, 2023, 228(6):724.
[38]
Plett H, Ricciardi E, Vacaru V, et al. Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence[J]. Int J Gynecol Cancer, 2023, 33(5):734-740.
[34]
Huang C Y, Cheng M, Lee N R, et al. Comparing paclitaxel-carboplatin with paclitaxel-cisplatin as the front-line chemotherapy for patients with FIGO IIIC serous-type tubo-ovarian cancer[J]. Int J Environ Res Public Health, 2020, 17(7):2213.
Färkkilä A, Pihlajoki M, Tauriala H, et al. Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro[J]. J Clin Endoc Metab, 2011, 96(12):E1973-81.
[40]
Bryk S, Färkkilä A, Bützow R, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience[J]. Int J Gynecol Cancer, 2015, 25(1):33-41.
[36]
Tao X, Sood A K, Deavers M T, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors[J]. Gynecol Oncol, 2009, 114(3):431-436.
[41]
Ohta M, Hara Y, Kashiwadate T, et al. Recurrence of adult granulosa cell tumor in the greater omentum 11 years after surgery[J]. Case Rep Gastroenterol,2021, 15(2):639-644.
[37]
How J A, Jazaeri A, Westin S N, et al. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial[J]. Invest New Drugs, 2021, 39(3):829-835.
[42]
Togashi K, Yoneyama T, Sutoh Yoneyama M, et al. Renal metastasis of ovarian granulosa cell tumor[J]. IJU Case Rep, 2022, 5(3):186-190.
[38]
Plett H, Ricciardi E, Vacaru V, et al. Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence[J]. Int J Gynecol Cancer, 2023, 33(5):734-740.
[43]
Gu Y, Wang D, Jia C, et al. Clinical characteristics and oncological outcomes of recurrent adult granulosa cell tumor of ovary: a retrospective study of seventy patients[J]. Acta Obstet Gynecol Scand, 2023, 102(6):782-790.
Groeneweg J W, Roze J F, Peters E D, et al. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring[J]. Gynecol Oncol, 2021, 162(2):413-420.
[40]
Bryk S, Färkkilä A, Bützow R, et al. Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience[J]. Int J Gynecol Cancer, 2015, 25(1):33-41.
[45]
Llano E, Todeschini A L, Felipe N, et al. The Oncogenic FOXL2 C134W mutation is a key driver of granulosa cell tumors[J]. Cancer Res, 2023, 83(2):239-250.
[41]
Ohta M, Hara Y, Kashiwadate T, et al. Recurrence of adult granulosa cell tumor in the greater omentum 11 years after surgery[J]. Case Rep Gastroenterol,2021, 15(2):639-644.
[46]
Wu L, Fidan K, Um J Y, et al. Telomerase: key regulator of inflammation and cancer[J]. Pharmacol Res, 2020, 155:104726.
[42]
Togashi K, Yoneyama T, Sutoh Yoneyama M, et al. Renal metastasis of ovarian granulosa cell tumor[J]. IJU Case Rep, 2022, 5(3):186-190.
[47]
Roze J F, Kutzera J, Koole W, et al. Familial occurrence of adult granulosa cell tumors: analysis of whole-genome germline variants[J]. Cancers (Basel), 2021, 13(10):2430.
[43]
Gu Y, Wang D, Jia C, et al. Clinical characteristics and oncological outcomes of recurrent adult granulosa cell tumor of ovary: a retrospective study of seventy patients[J]. Acta Obstet Gynecol Scand, 2023, 102(6):782-790.
[44]
Groeneweg J W, Roze J F, Peters E D, et al. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring[J]. Gynecol Oncol, 2021, 162(2):413-420.
[48]
Kim S, Kim S, Mun S, et al. Whole-exome sequencing reveals rare genetic variations in ovarian granulosa cell tumor[J]. Bosn J Basic Med Sci, 2022, 22(3):403-411.
[45]
Llano E, Todeschini A L, Felipe N, et al. The Oncogenic FOXL2 C134W mutation is a key driver of granulosa cell tumors[J]. Cancer Res, 2023, 83(2):239-250.
[46]
Wu L, Fidan K, Um J Y, et al. Telomerase: key regulator of inflammation and cancer[J]. Pharmacol Res, 2020, 155:104726.
[47]
Roze J F, Kutzera J, Koole W, et al. Familial occurrence of adult granulosa cell tumors: analysis of whole-genome germline variants[J]. Cancers (Basel), 2021, 13(10):2430.
[48]
Kim S, Kim S, Mun S, et al. Whole-exome sequencing reveals rare genetic variations in ovarian granulosa cell tumor[J]. Bosn J Basic Med Sci, 2022, 22(3):403-411.
2024, Vol. 35 
